Julian G. Hurdle

Texas A&M Health Science Center — United States

Medicine · Health Sciences

31h-index3.5kcitations78works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Clostridium difficile and Clostridium perfringens research(42), Antimicrobial Resistance in Staphylococcus(17), Helicobacter pylori-related gastroenterology studies(12), Antibiotic Resistance in Bacteria(11), Microscopic Colitis(11)

Publications78 total

Development of a high-throughput screening platform for <i>C. difficile</i> toxin synthesis inhibitors unveils meclizine as an antivirulence agent
Antimicrobial Agents and Chemotherapy·2025Open Access
Structural and Biochemical Characterization of <i>Fusobacterium nucleatum</i> Enoyl-ACP Reductase II (FabK) Reveals the Basis for Bacterial Species-Specific Inhibition
ACS Bio & Med Chem Au·2025Open Access
The microbiome-restorative potential of ibezapolstat for the treatment of <i>Clostridioides difficile</i> infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae
Antimicrobial Agents and Chemotherapy·2025· 2 citedOpen Access
Fidaxomicin resistance in <i>Clostridioides difficile</i> : a systematic review and predictive modeling with RNA polymerase binding sites
Antimicrobial Agents and Chemotherapy·2024· 4 citedOpen Access
Reduced Vancomycin Susceptibility in <i>Clostridioides difficile</i> Is Associated With Specific Ribotypes
Open Forum Infectious Diseases·2024· 6 citedOpen Access
Chemical genetic analysis of enoxolone inhibition of Clostridioides difficile toxin production reveals adenine deaminase and ATP synthase as antivirulence targets
Journal of Biological Chemistry·2024· 7 citedOpen Access
Evaluation of <i>Fusobacterium nucleatum</i> Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target
ACS Infectious Diseases·2024· 6 citedOpen Access
Reduced Vancomycin Susceptibility in <i>Clostridioides difficile</i> Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response
Clinical Infectious Diseases·2024· 28 citedOpen Access
<i>In vivo</i> evaluation of <i>Clostridioides difficile</i> enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
Antimicrobial Agents and Chemotherapy·2024· 3 citedOpen Access
<i>In vivo</i> evaluation of <i>Clostridioides difficile</i> enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy
2023Open Access
C. difficile intoxicates neurons and pericytes to drive neurogenic inflammation
Nature·2023· 54 citedOpen Access
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile
Nature Communications·2023· 53 citedOpen Access
Synthesis and evaluation of phenylimidazole FabK inhibitors as new Anti-C. Difficile agents
Bioorganic & Medicinal Chemistry·2023· 5 citedOpen Access
Surveillance of <i>Clostridioides difficile</i> Antimicrobial Resistance in the United States
Clinical Infectious Diseases·2023· 4 citedOpen Access
380. A molecular epidemiological exploration of reduced vancomycin susceptibility in <i>Clostridioides difficile</i>
Open Forum Infectious Diseases·2022Open Access
401. Rigor and Reproducibility of <i>Clostridioides difficile</i> susceptibility testing
Open Forum Infectious Diseases·2022Open Access
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant <i>Clostridioides difficile</i>
2022· 4 citedOpen Access
The licorice metabolite enoxolone attenuates <i>Clostridioides difficile</i> pathophysiology by corrupting its metabolic and toxin production networks
2022Open Access
The Ferrous Iron Transporter FeoB1 is Essential for <i>Clostridioides difficile</i> Toxin Production and Pathogenesis in Mice
2022· 7 citedOpen Access
Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
Antibiotics·2022· 37 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Richard Lee(22), Dianqing Sun(13), Xiaoqian Wu(12), Robin B. Lee(8), Kirk E. Hevener(7), Kevin W. Garey(7), Ravi K. R. Marreddy(7), David F. Bruhn(6), Aditi Deshpande(6), Michaël Scherman(5), Michael McNeil(5), Marcus M. Maddox(5), Wan‐Jou Shen(5), Abiola Olumuyiwa Olaitan(5), Anne J Gonzales-Luna(5), Philip Cherian(5), Alex J. O’Neill(4), Ian Chopra(4), Jianjun Qi(4), Bernd Meibohm(4)